BR112022024988A2 - Compostos e métodos para tratamento de infecções fúngicas - Google Patents

Compostos e métodos para tratamento de infecções fúngicas

Info

Publication number
BR112022024988A2
BR112022024988A2 BR112022024988A BR112022024988A BR112022024988A2 BR 112022024988 A2 BR112022024988 A2 BR 112022024988A2 BR 112022024988 A BR112022024988 A BR 112022024988A BR 112022024988 A BR112022024988 A BR 112022024988A BR 112022024988 A2 BR112022024988 A2 BR 112022024988A2
Authority
BR
Brazil
Prior art keywords
treatment
methods
compounds
fungal infections
fungal
Prior art date
Application number
BR112022024988A
Other languages
English (en)
Inventor
joy Shaw Karen
Schlamm Haran
R Hodges Michael
Original Assignee
Amplyx Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amplyx Pharmaceuticals Inc filed Critical Amplyx Pharmaceuticals Inc
Publication of BR112022024988A2 publication Critical patent/BR112022024988A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

COMPOSTOS E MÉTODOS PARA TRATAMENTO DE INFECÇÕES FÚNGICAS. A presente invenção refere-se a composições e métodos de uso das mesmas para o tratamento de infecções e doenças fúngicas.
BR112022024988A 2020-06-17 2021-06-16 Compostos e métodos para tratamento de infecções fúngicas BR112022024988A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063040450P 2020-06-17 2020-06-17
PCT/US2021/037578 WO2021257670A1 (en) 2020-06-17 2021-06-16 Compounds and methods for treating fungal infections

Publications (1)

Publication Number Publication Date
BR112022024988A2 true BR112022024988A2 (pt) 2022-12-27

Family

ID=79268375

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022024988A BR112022024988A2 (pt) 2020-06-17 2021-06-16 Compostos e métodos para tratamento de infecções fúngicas

Country Status (12)

Country Link
US (1) US20230233586A1 (pt)
EP (1) EP4167998A4 (pt)
JP (1) JP2023530936A (pt)
KR (1) KR20230024375A (pt)
CN (1) CN115884775A (pt)
AU (1) AU2021293911B2 (pt)
BR (1) BR112022024988A2 (pt)
CA (1) CA3187268A1 (pt)
IL (1) IL299057A (pt)
MX (1) MX2022016179A (pt)
TW (1) TWI888580B (pt)
WO (1) WO2021257670A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220148881A (ko) 2020-03-04 2022-11-07 앰플릭스 파마슈티컬스, 인크. 진균 감염 치료에서의 화합물의 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI385169B (zh) * 2005-10-31 2013-02-11 Eisai R&D Man Co Ltd 經雜環取代之吡啶衍生物及含有彼之抗真菌劑
US8513287B2 (en) * 2007-12-27 2013-08-20 Eisai R&D Management Co., Ltd. Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
US20130288956A1 (en) * 2010-11-05 2013-10-31 Eisai R&D Management Co., Ltd. Combined pharmaceutical composition as antifungal agent
CN112996527B (zh) * 2018-08-31 2025-02-21 巴斯利尔药物阿尔施维尔国际股份公司 用于治疗真菌感染的化合物和方法
US11819503B2 (en) * 2019-04-23 2023-11-21 F2G Ltd Method of treating coccidioides infection
KR20220148881A (ko) * 2020-03-04 2022-11-07 앰플릭스 파마슈티컬스, 인크. 진균 감염 치료에서의 화합물의 용도

Also Published As

Publication number Publication date
MX2022016179A (es) 2023-04-20
CN115884775A (zh) 2023-03-31
US20230233586A1 (en) 2023-07-27
KR20230024375A (ko) 2023-02-20
IL299057A (en) 2023-02-01
JP2023530936A (ja) 2023-07-20
EP4167998A1 (en) 2023-04-26
CA3187268A1 (en) 2021-12-23
TW202214258A (zh) 2022-04-16
WO2021257670A1 (en) 2021-12-23
AU2021293911B2 (en) 2024-11-14
AU2021293911A1 (en) 2023-01-19
TWI888580B (zh) 2025-07-01
EP4167998A4 (en) 2024-07-17

Similar Documents

Publication Publication Date Title
CO2023015484A2 (es) Compuesto, composiciones y métodos para el tratamiento de trastornos
CO2019007863A2 (es) Derivados de benzooxazol como inmunomoduladores
CO2020001244A2 (es) Derivados de quinolina para tratar infecciones con helmintos
BR112021024236A2 (pt) Proteínas multiespecíficas
MX2022005256A (es) Inhibidores de cd73.
UY37461A (es) 1,2,4 – triazolonas 2,4,5 trisustituida
CL2021001395A1 (es) Compuestos derivados de panteteínas cíclicas; composición farmacéutica que los comprende; y su uso para aumentar las concentraciones de acetil-coa, para el tratamiento de cáncer, enfermedad inflamatoria, enfermedad neurodegenerativa, esclerosis múltiple, entre otras enfermedades.
MX2018012544A (es) Nuevos derivados de pirazolopirimidina.
BR112016020199A8 (pt) composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso
BR112023014973A2 (pt) Derivados de urolitina e métodos de uso dos mesmos
MX383164B (es) Composicion que contiene arn para tratamiento de enfermedades tumorales.
CO2021002977A2 (es) Dimetilaminoazetidinaminas como inhibidores de jak
CO2020013876A2 (es) Nuevos derivados de quinolina
CL2020001147A1 (es) Compuestos antibacterianos
CL2019001749A1 (es) Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
BR112021025645A2 (pt) Degradação de proteína alvo de parp14 para uso em terapia
CO2022000481A2 (es) Inhibidores de enzimas
DOP2020000100A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
CL2022000967A1 (es) Composiciones y métodos para el tratamiento de enfermedades hepáticas
MX2020011826A (es) Composiciones de combinacion que comprenden compuestos de bisfluoroalquil-1,4-benzodiazepinona y metodos de uso de las mismas.
BR112021011325A2 (pt) Derivados de rapamicina
MX2021015770A (es) Inhibidores macrociclicos de mcl-1.
MX2021003643A (es) Derivados de terpenoides y usos de los mismos.
CY1122374T1 (el) Βιοτινη για την θεραπευτικη αντιμετωπιση απομυελινωτικων νευροπαθειων
MX2020001808A (es) Nuevos compuestos.

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: AMPLYX PHARMACEUTICALS, INC. (US)

B25A Requested transfer of rights approved

Owner name: BASILEA PHARMACEUTICA INTERNATIONAL AG, ALLSCHWIL (CH)